MBHB Partners Kevin Noonan and Andrew Williams Co-Author BioLogical Quarterly Article Entitled, “First U.S. Biosimilar Application Approved — But What About the Patent Issues?”

McDonnell Boehnen Hulbert & Berghoff LLP partners Dr. Kevin E. Noonan and Dr. Andrew W. Williams co-authored an article entitled, “First U.S. Biosimilar Application Approved — But What About the Patent Issues?” that appears in the March 31, 2015 online edition of iBIO’s Biological Quarterly. After a seemingly interminable delay (certainly for policymakers who were hoping for a “quick fix” with regard to biologic drug prices), the first biosimilar application was accepted and, in short order, approved by the Food and Drug Administration. And almost concurrently, a U.S. District Court denied Amgen’s motion for a preliminary injunction, thereby clearing the way for the drug to be put on the market (albeit now without risk of patent infringement liability). View the article

Search by Type
Menu
Menu